eligibility_summary
Inclusion: 18–75, R/R MM after ≥3 lines (incl PI+IMiD) with progression ≤12 mo from last therapy, measurable disease (M‑protein/sFLC per IMWG), adequate organ function, ECOG ≤1, survival ≥12 wks, contraception, consent. Exclusion: allergy, recent CAR‑T/gene tx, PCL/WM/POEMS/AL, major CV/CVA/PE/DVT/lung disease, HBV/HCV/syphilis/HIV/autoimmune, active malignancy, CNS disease, recent transplant/GVHD, anti‑MM tx/radiation/live vaccine, psych/substance abuse, pregnancy, other trial, PI discretion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: YTS104, an autologous, lentiviral-transduced dual STAR-T cell therapy (cellular immunotherapy) targeting BCMA and LILRB4. Mechanism: synthetic antigen receptors engage BCMA and LILRB4 to signal via native TCR/CD3, activating T-cell cytotoxicity against BCMA+ myeloma cells and LILRB4+ cells in the tumor milieu, aiming to boost efficacy and reduce antigen escape/immunosuppression. Conditioning: fludarabine (antimetabolite) plus cyclophosphamide (alkylator) for lymphodepletion to support engraftment/expansion. Targets/pathways: BCMA on malignant plasma cells, LILRB4 (ILT3)-expressing immune/tumor cells, activation of TCR/CD3 signaling in engineered T cells. Dose: 1E6–1E7 cells/kg IV, repeat dosing allowed.